162 related articles for article (PubMed ID: 25962411)
1. Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay.
van der Ryst E; Heera J; Demarest J; Knirsch C
Ann N Y Acad Sci; 2015 Jun; 1346(1):7-17. PubMed ID: 25962411
[TBL] [Abstract][Full Text] [Related]
2. Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists.
Poveda E; Alcamí J; Paredes R; Córdoba J; Gutiérrez F; Llibre JM; Delgado R; Pulido F; Iribarren JA; García Deltoro M; Hernández Quero J; Moreno S; García F
AIDS Rev; 2010; 12(3):135-48. PubMed ID: 20842202
[TBL] [Abstract][Full Text] [Related]
3.
Gracias S; El Yaalaoui I; Visseaux B; Charpentier C; Descamps D; Martin C; Lermechain F; Plantier J-C; Alessandri-Gradt E
Microbiol Spectr; 2024 Jul; 12(7):e0389523. PubMed ID: 38809042
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.
Bon I; Clò A; Borderi M; Colangeli V; Calza L; Morini S; Miserocchi A; Cricca M; Gibellini D; Re MC
Int J Infect Dis; 2013 Oct; 17(10):e875-82. PubMed ID: 23597487
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
[TBL] [Abstract][Full Text] [Related]
6. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents.
MacArthur RD; Novak RM
Clin Infect Dis; 2008 Jul; 47(2):236-41. PubMed ID: 18532888
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
[TBL] [Abstract][Full Text] [Related]
8. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
Symons J; van Lelyveld SF; Hoepelman AI; van Ham PM; de Jong D; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2011 Apr; 66(4):890-5. PubMed ID: 21393136
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism.
Roche M; Jakobsen MR; Sterjovski J; Ellett A; Posta F; Lee B; Jubb B; Westby M; Lewin SR; Ramsland PA; Churchill MJ; Gorry PR
J Virol; 2011 May; 85(9):4330-42. PubMed ID: 21345957
[TBL] [Abstract][Full Text] [Related]
10. Determination of HIV tropism and its use in the clinical practice.
Pérez-Olmeda M; Alcami J
Expert Rev Anti Infect Ther; 2013 Dec; 11(12):1291-302. PubMed ID: 24191978
[TBL] [Abstract][Full Text] [Related]
11. A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients.
Kagan RM; Johnson EP; Siaw M; Biswas P; Chapman DS; Su Z; Platt JL; Pesano RL
PLoS One; 2012; 7(9):e46334. PubMed ID: 23029482
[TBL] [Abstract][Full Text] [Related]
12. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
Cooper DA; Heera J; Goodrich J; Tawadrous M; Saag M; Dejesus E; Clumeck N; Walmsley S; Ting N; Coakley E; Reeves JD; Reyes-Teran G; Westby M; Van Der Ryst E; Ive P; Mohapi L; Mingrone H; Horban A; Hackman F; Sullivan J; Mayer H
J Infect Dis; 2010 Mar; 201(6):803-13. PubMed ID: 20151839
[TBL] [Abstract][Full Text] [Related]
13. [Methods for determination of HIV tropism and their clinical use].
Gutiérrez F; Rodríguez JC; García F; Poveda E
Enferm Infecc Microbiol Clin; 2011 Dec; 29 Suppl 5():45-50. PubMed ID: 22305669
[TBL] [Abstract][Full Text] [Related]
14. Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.
Gonzalez-Serna A; McGovern RA; Harrigan PR; Vidal F; Poon AF; Ferrando-Martinez S; Abad MA; Genebat M; Leal M; Ruiz-Mateos E
Antimicrob Agents Chemother; 2012 Mar; 56(3):1202-7. PubMed ID: 22143533
[TBL] [Abstract][Full Text] [Related]
15. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
16. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
[TBL] [Abstract][Full Text] [Related]
17. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.
Swenson LC; Mo T; Dong WW; Zhong X; Woods CK; Jensen MA; Thielen A; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
J Infect Dis; 2011 Jan; 203(2):237-45. PubMed ID: 21288824
[TBL] [Abstract][Full Text] [Related]
18. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.
Seclén E; González Mdel M; Lapaz M; Rodríguez C; del Romero J; Aguilera A; de Mendoza C; Soriano V; Poveda E
J Antimicrob Chemother; 2010 Dec; 65(12):2502-4. PubMed ID: 20940179
[TBL] [Abstract][Full Text] [Related]
19. Maraviroc: a new CCR5 antagonist.
Sayana S; Khanlou H
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
[TBL] [Abstract][Full Text] [Related]
20. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
Hunt JS; Romanelli F
Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
